Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

Leo R Zacharski; Maria Benedetta Donati; Frederick R Rickles

doi:10.1055/s-0038-1649580

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1993; 70(02): 357-360
DOI: 10.1055/s-0038-1649580

Scientific and Standardization Committee Communications

Schattauer GmbH Stuttgart

Registry of Clinical Trials of Antithrombotic Drugs in Cancer: Second Report

The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Subcommittee on Hemostasis and Malignancy

Leo R Zacharski

¹The VA Medical & Regional Office Center, White River Junction, Vermont, and the Department of Medicine, Dartmouth Medical School, Hanover, New Hampshire U.S.A.

,

Maria Benedetta Donati

²The Istituto di Richerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy

,

Frederick R Rickles

³The VA Medical Center, Newington, Connecticut, and the Department of Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, U.S.A.

› Author Affiliations

Abstract

PDF Download

PDF (761 kb)

References

References
1 Zacharski LR, Donati MB. Registry of clinical trials of antithrombotic drugs in cancer. Thromb Haemostas 1989; 61: 526-528
2 Zacharski LR. Anticoagulation in the treatment of cancer in man. In: Malignancy and the Hemostatic System. Donati M, Davidson J, Garattini S. (eds) Raven Press; New York: 1981: 113-128
3 Maurer LH. Personal communication.
4 Lerbeau B. Personal communication.
5 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell CJ, Forcier RJ, Edwards RL, Headley E. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of the VA Cooperative Study 75. Cancer 1984; 53: 2046-2052
6 Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry MC, Hirsh V, Skarin A, Kopel S. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group. Br J Clin Oncol 1989; 7: 993-1002
7 Lebeau B, Chastang CL, Brechot JM. Subcutaneous heparin treatment increases complete reponse rate and overall survival in small cell lung cancer (SCLC). Lung Cancer 1991; 7 (Suppl. 00) 129
8 Zacharski LR, Cornell CJ, Haakenson CM, Ballard HS, Crum ED, Johnson GJ, Levine J, Hong WK. Effect of RA-233 (Mopidamole) on survival in carcinoma of the lung and colon: Final report of VA Cooperative Study #188. J Natl Cancer Inst 1988; 80: 9087-9141
9 Blaha H, Dierkesmann R, Feuerer W, Gatzemaier U, Geser C, Lemme J, Mall W, Ritscher R. Adjuvante Therapie des nichtkleinzelligen Bronchialkarzinoms mit Mopidamol. Pneumologie 1989; 43: 299-304
10 Thun M, Namboodiri M, Heath CJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1595-1596
11 Rosenberg L, Palmer J, Zauber A, Warshauer M, Stolley P, Shapiro S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991; 83: 355-358
12 Kune G, Kune S, Watson L. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-4404
13 Paganini-Hill A, Chao A, Ross R, Henderson B. Aspirin use and chronic diseases – a cohort study in the elderly. Br Med J 1989; 299: 1247-1250
14 Labayle D, Fischer D, Vielh P. Sulindac causes regression of rectal polyp in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639
15 Waddell W, Ganser G, Cerise E, Loughry R. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179
16 Rigan J, Pique J, Rubio E, Planas R, Tarrech J, Bordas J. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991; 115: 952-954
17 Baron J, Greenberg E. Could aspirin really prevent colon cancer?. N Engl J Med 1991; 325: 1644-1645
18 Rickies FR, Hancock WW, Edwards RL, Zacharski LR. Antimetastaic agents. I. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemostas 1988; 14: 88-94
19 Zacharski L, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumor tissue: Implications for cancer therapy. Blood Coag Fibrinolys 1990; 1: 71-78
20 Zacharski LR, Wojtukiewcz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin Hemostas Thromb 1992; 18: 104-116
21 Calvo PA, Harguindey SS, Aparicio LA, Dy C, Gil A, Rocha E. Urokinase and combination chemotherapy for treatment of small cell carcinoma of the lung. Cancer Treat Symp 1985; 2: 105-108
22 Calvo FA, Santos M, Hidalgo OF. Urokinase-combination chemotherapy in small cell lung cancer: A phase II study. Proc ASCO 1990; 9: 237
23 Calvo FA, Hidalgo OF, Gonzalez F, Rebollo J, Martin AlgarraS, Ortiz de UrbinaD, Brugarolas A. Urokinase combination chemotherapy in small cell carcinoma of the lung. A phase II study. Cancer 1992; 70: 2624-2630
24 Monden T, Morimoto H, Shimano T, Yagyu T, Murotani M, Nagaola H, Kawasaki Y, Kobayashi T. Use of fibrinogen to enhance the antitumor effect of OK-432. Cancer 1992; 69: 636-642
25 Wojtukiewicz MZ, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, Stump DC. Indirect activation of blood coagulation in colon cancer. Thromb Haemostas 1989; 62: 1062-1066
26 Astedt B, Glifberg I, Mattson W, Trope C. Arrest of growth of ovarian tumor by tranexamic acid. J Am Med Assoc 1977; 238: 154-155
27 Astedt B. Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 1980; 3 (Suppl. 00) 74-76
28 Kikuchi Y, Kizawa I, Oomori K, Matsuda M, Kato K. Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amounts of ascites. Acta Obstet Gynecol Scand 1986; 65: 453-456
29 Serdengecti S, Buyuskunal E, Molinas N, Demirelli F, Berkards N, Eyuboglu H, Derman U, Berkarda B. Overall survival results of nonsmall cell lung cancer patients: chemotherapy alone versus chemotherapy with combined immunomodulation. Chemiotherapia 1988; 7: 122-126
30 Ornstein D, Zacharski LR, Memoli VA, Kisiel W, Kudryk BJ, Hunt J, Rousseau SM, Stump DC. Coexistent macrophage procoagulant and tumor cell plasminogen activator in adenocarcinoma and squamous cell carcinoma of the lung. Cancer 1991; 68: 1061-1067
31 Hansen R, Schuetz M, Vukelich M, Blake D, Anderson T. A phase II study of 5-fluorouracil (5 FU) infusion interferon alpha, and dipyridamole in advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 154
32 Zaniboni A, Marpicati P, Simoncini E, Montini E, Meriggi F, Arcangeli G, Bonera F, Braga M, Ragni F, Marini G. Fluorouracil, high-dose folinic acid, low dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. J Chemother 1991; 3: 180-182
33 Migeod F, Gerlach D, Kress M, Hoffman W, Farroukh R, Sieber S. Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyridamole and mitomycin C. Onkologie 1988; 11 (Suppl. 02) 14-20
34 Wereldsma J, Bruggink E, Meijer W, Roukema J, van Putten W. Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Cancer 1990; 65: 425-432
35 Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Metast 1991; 9: 3-11
36 Lipton A, Harvey H, Walker BRD, Valdivia D, Barnes S, Gordon R, Whitehershey D, Bartholomew MJ, Warzawski N, Antle CE. Chemotherapy plus RA-233 in the treatment of oat-cell lung cancer. Am J Clin Oncol – Cancer Clin Trials 1989; 12: 259-263
37 Nieminen U, Kauppila A, Gronroos M, Kuoppala T, Vayrynen M. Placebo-controlled study on the efficacy of the pyrimido-pyrmidine derivative RA-233 in ovarian cancer. Gynecol Oncol 1990; 36: 226-231
38 Daniel F, Rao D, Tyrrell C. A pilot study of stanozolol for advanced breast carcinoma. Cancer 1991; 67: 2966-2968
39 Waddell WR, Kirsch WM. Testolactone, salindac, warfarin, and vitamin K1 for unresectable desmoid tumors. Am J Surg 1991; 161: 416-421
40 Israel L, Breau J, Morere J, Boaziz C. Anticancer effects of oral and intratumoral prostaglandin inhibitors. In: Ercosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Honn K, Marnett L, Nigam S, Walden TJ. (eds) Klewer; Boston, IL: 1991: 487-488
41 Cregan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TT, Geeraers LH, Veeder MH, Gesme Jr DH. et al. A randomized prospective assessment of recombinant leukocyte. A human interferon with or without aspirin in advanced renal adenocarcinoma. J Clin Oncol 1991; 12: 2104-2109
42 Murphy B, Rynard S, Pennington K, Grosh W, Loehrer PJ. A phase II trial of vinblastine (VLB) plus dipyridamole (DP) in advanced renal cell carcinoma (RCC): A Hoosier oncology group study. Proc Am Soc Clin Oncol 1991; 10: 176
43 Isacoff WH, Jacobs AD, Taylor O. Continuous infusion (CI) 5-fluorouracil (5-FU) combined with calcium leucovrin (LV), mitomycin-C (mito-C), and dipyridamole (D) in advanced colorectal carcinoma. Proc Am Soc Clin Oncol 1991; 10: 154
44 Kohne-Wompner CH, Wilke H, Weiss W, Hiddemann W, Gropp C, Schmitz-Hubner U, Zohrman HP, Bodenstein H, Preusser P, Urbanitz D, Hotz J, Preiss J, Knuth A, Schwark J, Bade J, Kohler B, Schmoll HJ. 5-FU, folinic acid (FA) +/- dipyridamole (D) in advanced and progressive colorectal cancer (CC) – a randomized multicenter phase II trial. Proc Am Soc Clin Oncol 1990; 10: 123
45 Higano CS, Livingston RB. Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial. Cancer Chemother Pharmacol 1989; 23: 259-262
46 Wilson JK, Fischer PH, Tutsch K, Alberti D, Simon K, Hamilton RD, Bruggink J, Koeller JM, Tormey DC, Earhart RH. Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer Res 1988; 48: 5585-5590
47 Budd GT, Jayaraj A, Grabowski D, Adelstein D, Bauer L, Boyett J, Bukowski R, Murthy S, Weick J. Phase I trial of dipyridamole with 5-fluorouracil and folinic acid. Cancer Res 1990; 50: 7206-7211
48 Sakaguchi Y, Maehara Y, Emi Y, Kusumoto T, Kohnoe S, Sugimachi K. Dipyridamole combination chemotherapy can be used safely in treating gastic cancer patients. Anticancer Drugs 1991; 2: 139-143
49 Fountzilas G, Zisiadis A, Kosmidis P, Basdanis G, Makrantonakis P, Paspatis A, Tsavdaridis D, Tsavaris N, Aletras O, Tourkantonis A. High-dose leucovarin, fluorouracil and oral dipyridamole in the treatment of advanced colorectal cancer. Anticancer Res 1991; 11: 865-868
50 Tsavaris N, Zinelis A, Karvorinis N, Beldecos D, Mylonacis N, Zamanis N, Bacoyannis C, Valilis P, Antonopoulos A, Kosmidis P. Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with 5-fluorouracil, folinic acid and dipyridamole. J Chemother 1990; 2: 123-126
51 Kobayaski T, Sasaki T, Ibuka T, Imai K, Monma K, Sakaki N, Tabata I, Ishirvata J, Onozawa Y, Ohno T. Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation. Gan To Kagaku Ryoho 1992; 19: 69-74